Senda Ajroud-Driss

Grants

Grants per year 1999 2020 2021 2022 2027

• 22 Active
• 57 Finished

Grants per year

Search results

• Active

  An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012

  Ajroud-Driss, S. (PD/PI)

  Clene Nanomedicine, Inc., National Institute of Neurological Disorders and Stroke

  9/19/24 → 8/31/27

  Project: Research project

• Acceleration Centers of Enrollment (ACE)

  Ajroud-Driss, S. (PD/PI)

  Massachusetts General Hospital

  8/1/24 → 7/31/26

  Project: Research project

• Prot #EDG-5506-201: A Phase 2 Randomized, Double-blind, Placebo controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents with Becker Muscular Dystrophy

  Ajroud-Driss, S. (PD/PI)

  Edgewise Therapeutics, Inc.

  12/14/23 → 12/14/26

  Project: Research project

• An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine

  Ajroud-Driss, S. (PD/PI)

  Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke

  9/25/23 → 8/31/27

  Project: Research project

• Clinic-based Multicenter ALS Natural History Data Collection- Supplement

  Ajroud-Driss, S. (PD/PI)

  University of Minnesota, Food and Drug Administration

  9/1/23 → 8/31/26

  Project: Research project

• (OE) Prot #CNMAu8.EAP02: A Second Expanded Access Protocol for Amyotrophic Lateral Sclerosis with CNM-Au8

  Ajroud-Driss, S. (PD/PI)

  Clene Nanomedicine, Inc.

  5/11/23 → 5/11/26

  Project: Research project

• UMMS-ASO-STMN2 Study - Year 2

  Ajroud-Driss, S. (PD/PI), Ajroud-Driss, S. (PD/PI) & Ajroud-Driss, S. (PD/PI)

  Hopewell Fund

  11/1/22 → 12/31/24

  Project: Research project

• An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis

  Ajroud-Driss, S. (PD/PI)

  Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke

  9/28/22 → 8/31/25

  Project: Research project

• Clinic-based Multicenter ALS Natural History Data Collection

  Ajroud-Driss, S. (PD/PI) & Ajroud-Driss, S. (PD/PI)

  University of Minnesota, Food and Drug Administration

  9/20/22 → 8/31/26

  Project: Research project

  • Natural History Data 100%
  • Natural History 100%
  • Clinic-based 100%
  • Real-World Data 100%
  • Disease State 100%

• A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects with Amyotrophic Lateral Scle

  Ajroud-Driss, S. (PD/PI)

  ICON Clinical Research, LLC, Mitsubishi Tanabe Pharma America, Inc.

  8/8/22 → 8/8/25

  Project: Research project

• Prot#A35-006: EXPANDED ACCESS TRIAL OF AMX0035 FOR AMYOTROPHIC LATERAL SCLEROSIS: An Intermediate Size, Expanded Access Protocol to Provide AMX0035, A Fixed Combination of Sodium Phenylbutyrate(PB) and Taurursodiol (TURSO), for the Treatment of Adult Pati

  Ajroud-Driss, S. (PD/PI)

  Amylyx Pharmaceuticals, Inc.

  6/8/22 → 6/8/25

  Project: Research project

• Prot#16970: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants with Amyotrophic Lateral Sclerosis, Followed by an Open-Label Extension

  Ajroud-Driss, S. (PD/PI)

  Sanofi US Services Inc.

  3/29/22 → 3/29/25

  Project: Research project

• Prot#WP-0512-003: A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

  Ajroud-Driss, S. (PD/PI) & Ajroud-Driss, S. (PD/PI)

  DP Clinical, Inc., Woolsey Pharmaceuticals, Inc.

  3/3/22 → 3/22/25

  Project: Research project

• Protocol Number: A35-004 - Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)

  Ajroud-Driss, S. (PD/PI)

  Julius Clinical Research B.V, Amylyx Pharmaceuticals, Inc.

  1/12/22 → 1/12/25

  Project: Research project

• Prot #233AS303: A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

  Ajroud-Driss, S. (PD/PI)

  DrugDev Inc., Biogen MA Inc.

  8/12/21 → 5/31/26

  Project: Research project

• Prot#AB19001: A Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination with Riluzole Versus Placebo in Combination with Riluzole in the Treatmen

  Ajroud-Driss, S. (PD/PI)

  AB Science

  2/26/21 → 12/31/24

  Project: Research project

• Prot# 233AS102: An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 M

  Ajroud-Driss, S. (PD/PI)

  Quintiles, Inc., Biogen MA Inc.

  11/24/20 → 9/30/25

  Project: Research project

• HEALEY ALS Platform Trial Regimen-Specific Appendix (RSA) D to Master Protocol PRIDOPIDINE | Home Spirometry and Open-Label Extension (OLE) Period

  Ajroud-Driss, S. (PD/PI), Ajroud-Driss, S. (PD/PI) & Ajroud-Driss, S. (PD/PI)

  Massachusetts General Hospital, Prilenia Neurotherapeutics Ltd

  9/4/20 → 3/14/25

  Project: Research project

• Oxidative Markers and Efficacy in ALS/MND Phenotypes Treated with Edaravone: Proof of Concept

  Ajroud-Driss, S. (PD/PI)

  Loma Linda University, Mitsubishi Tanabe Pharma America, Inc.

  9/2/20 → 9/2/25

  Project: Research project

• HEALEY ALS Platform Trial Platform-Level Site Activities

  Ajroud-Driss, S. (PD/PI) & Ajroud-Driss, S. (PD/PI)

  Massachusetts General Hospital

  3/23/20 → 12/31/24

  Project: Research project

• Prot# ALN-TTRSC02-002: HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis(hATTR Amyloidosis)

  Ajroud-Driss, S. (PD/PI)

  Medpace, Inc., Alnylam Pharmaceuticals, Inc.

  2/22/19 → 3/31/26

  Project: Research project

• Consortium Member and Peripheral Neuropathy Research Registry Agreement

  Ajroud-Driss, S. (PD/PI), Ajroud-Driss, S. (PD/PI) & Ajroud-Driss, S. (PD/PI)

  Foundation for Peripheral Neuropathy

  1/1/18 → 12/31/24

  Project: Research project